Change in symptom and quality of life in COPD by Budesonide/Glycopyrronium/Formoterol fumarate pressurized metered dose inhaler (BGF pMDI)

Trial Identifier: D5980R00033
Sponsor: AstraZeneca
NCTID:: NCT05219630
Start Date: May 2022
Primary Completion Date: May 2023
Study Completion Date: May 2023
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan